Health & Fitness
Health and Fitness
Health and Fitness
Tue, May 31, 2011
Mon, May 30, 2011
Fri, May 27, 2011 AVEO Pharmaceuticals, Inc. to Present at the Jefferies 2011 Global Healthcare Conference
CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Jefferies 2011 Global Healthcare Conference on Tuesday, June 7, 2011 at 10:30 a.m. (EDT) in New York City.
A live webcast of AVEO's presentation can be accessed by visiting the investors section of the companya™s website at investor.aveopharma.com. A replay of the webcast will be archived on the AVEO website for two weeks following the presentation.
About AVEO
AVEO Pharmaceuticals (NASDAQ: AVEO) is a cancer therapeutics company committed to discovering, developing and commercializing targeted therapies to impact patientsa™ lives. The companya™s lead product candidate, tivozanib, is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in patients with advanced renal cell carcinoma, as well as additional clinical studies in other solid tumor types. AVEOa™s second most advanced product candidate, ficlatuzumab (AV-299), is a potent, functional anti-HGF/c-MET pathway antibody that is currently in Phase 2 clinical development. AVEOa™s proprietary Human Response Platforma" is designed to offer the company a unique advantage in cancer drug development and has provided a discovery engine for multiple therapeutic targets. This approach has resulted in a promising pipeline of monoclonal antibodies against novel targets including HGF, ErbB3, RON, Notch and FGFR. For more information, please visit the companya™s website at www.aveopharma.com.
